MX346002B - Anticuerpos anti-vegf y sus usos. - Google Patents

Anticuerpos anti-vegf y sus usos.

Info

Publication number
MX346002B
MX346002B MX2014001638A MX2014001638A MX346002B MX 346002 B MX346002 B MX 346002B MX 2014001638 A MX2014001638 A MX 2014001638A MX 2014001638 A MX2014001638 A MX 2014001638A MX 346002 B MX346002 B MX 346002B
Authority
MX
Mexico
Prior art keywords
vegf antibodies
vegf
antibodies
overproduction
activity
Prior art date
Application number
MX2014001638A
Other languages
English (en)
Inventor
Harding Fiona
Akamatsu Yoshiko
B Dubridge Robert
B Powers David
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42543312&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346002(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of MX346002B publication Critical patent/MX346002B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a anticuerpos dirigidos al factor de crecimiento endotelial vascular ("VEGF") y a los usos de tales anticuerpos, por ejemplo para tratar enfermedades asociadas con actividad y/o sobreproducción de VEGF.
MX2014001638A 2009-06-17 2010-06-17 Anticuerpos anti-vegf y sus usos. MX346002B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21800509P 2009-06-17 2009-06-17
PCT/US2010/039029 WO2010148223A2 (en) 2009-06-17 2010-06-17 Anti-vegf antibodies and their uses

Publications (1)

Publication Number Publication Date
MX346002B true MX346002B (es) 2017-03-01

Family

ID=42543312

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011013781A MX2011013781A (es) 2009-06-17 2010-06-17 Anticuerpos anti-vegf y sus usos.
MX2014001638A MX346002B (es) 2009-06-17 2010-06-17 Anticuerpos anti-vegf y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011013781A MX2011013781A (es) 2009-06-17 2010-06-17 Anticuerpos anti-vegf y sus usos.

Country Status (25)

Country Link
US (1) US9079953B2 (es)
EP (2) EP2443150B1 (es)
JP (1) JP5785941B2 (es)
KR (1) KR20120034739A (es)
CN (1) CN102482349B (es)
AU (1) AU2010262836B2 (es)
BR (1) BRPI1012321A8 (es)
CA (1) CA2765755C (es)
CL (1) CL2011003182A1 (es)
CO (1) CO6480962A2 (es)
CR (1) CR20110653A (es)
EC (1) ECSP12011584A (es)
ES (2) ES2534355T3 (es)
GT (1) GT201100326A (es)
HK (1) HK1211961A1 (es)
IL (2) IL216835A0 (es)
MX (2) MX2011013781A (es)
NZ (1) NZ596837A (es)
PE (1) PE20120622A1 (es)
RU (1) RU2567639C2 (es)
SG (2) SG10201403327WA (es)
TW (1) TWI510248B (es)
UA (1) UA104626C2 (es)
WO (1) WO2010148223A2 (es)
ZA (1) ZA201109098B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
MX358864B (es) * 2011-04-12 2018-09-06 Gangagen Inc Polipeptidos antibacterianos quimericos.
JP6154900B2 (ja) 2012-07-13 2017-06-28 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
EP3502267A1 (en) 2012-09-19 2019-06-26 F. Hoffmann-La Roche AG Methods and compositions for preventing norleucine misincorporation into proteins
US9777067B2 (en) 2012-09-27 2017-10-03 Massachusetts Institute Of Technology HER2- and VEGF-A-binding proteins with enhanced stability
KR101279895B1 (ko) * 2012-10-24 2013-06-28 주식회사 진흥기공 유체 이송용 덕트에 결합 사용되는 댐퍼의 이중 브레이드 밀폐 장치
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CN105188749B (zh) 2012-12-21 2017-12-19 西雅图基因公司 抗ntb‑a抗体及相关组合物和方法
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA2911087A1 (en) * 2013-04-30 2014-11-06 Harish Shandilya Novel cloning, expression & purification method for the preparation of ranibizumab
US20150017163A1 (en) * 2013-07-12 2015-01-15 Ophthotech Corporation Methods for Treating or Preventing Ophthalmological Conditions
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
WO2015164723A1 (en) 2014-04-25 2015-10-29 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016010002A1 (ja) * 2014-07-14 2016-01-21 中外製薬株式会社 タンパク質のエピトープを同定するための方法
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
CN108148134B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
KR20180104635A (ko) * 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
SG10202008378UA (en) * 2016-04-15 2020-10-29 Regenxbio Inc Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
EP3452103A1 (en) 2016-04-15 2019-03-13 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CN106039309B (zh) * 2016-06-30 2024-04-19 中国人民解放军总医院第一附属医院 用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
US20200115443A1 (en) * 2018-10-12 2020-04-16 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
CN111423512B (zh) * 2019-01-10 2024-01-05 北京比洋生物技术有限公司 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN111363038A (zh) * 2020-03-26 2020-07-03 北京纽安博生物技术有限公司 抗VEGF单域抗体及其人源化、单域抗体和IgG1-Fc构建的融合蛋白和应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途
PE20240115A1 (es) 2020-12-01 2024-01-22 Akouos Inc Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular
CN116897052A (zh) * 2021-03-04 2023-10-17 百奥泰生物制药股份有限公司 抗vegf抗体制剂
WO2023150142A1 (en) 2022-02-02 2023-08-10 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PT1787999E (pt) * 1997-04-07 2010-11-11 Genentech Inc Anticorpos anti-vegf
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
EP1950300A3 (en) 1998-11-18 2011-03-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
DE69926536T3 (de) * 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6979559B2 (en) * 2000-10-12 2005-12-27 Marical, Inc. Polyvalent cation-sensing receptor in atlantic salmon
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
ATE318890T1 (de) * 2000-12-14 2006-03-15 Genentech Inc Bakterielle wirtstämme
ES2312494T3 (es) 2000-12-14 2009-03-01 Genentech, Inc. Produccion de anticuerpos completos en celulas procariotas.
CA2369893A1 (en) 2001-02-12 2002-08-12 Warner-Lambert Company Vegf responsive cell-based assay for determining vegf bioactivity
US20040010376A1 (en) * 2001-04-17 2004-01-15 Peizhi Luo Generation and selection of protein library in silico
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20030022240A1 (en) * 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030224397A1 (en) * 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
CA2485732A1 (en) 2002-05-20 2003-12-04 Abmaxis, Inc. Generation and selection of protein library in silico
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
CA2513113A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
ME00425B (me) * 2003-05-30 2011-10-10 Genentech Inc Liječenje sa anti-vegf antitijelima
PT3095793T (pt) * 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
KR20070057839A (ko) * 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
MX2007004374A (es) * 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
AU2005296277A1 (en) 2004-10-12 2006-04-27 Amprotein Corporation Chimeric protein
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
JP2009515516A (ja) * 2005-11-14 2009-04-16 バイオレン・インク 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
WO2007059336A1 (en) 2005-11-18 2007-05-24 Nextrom Oy Method and apparatus for manufacturing water-free optical fiber preforms
JP2009516513A (ja) * 2005-11-21 2009-04-23 ラボラトワール セローノ ソシエテ アノニム ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用
WO2007087266A2 (en) * 2006-01-23 2007-08-02 Errico Joseph P Methods and compositions of targeted drug development
AU2007272224B2 (en) * 2006-07-10 2013-05-02 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US20090053786A1 (en) * 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions

Also Published As

Publication number Publication date
GT201100326A (es) 2013-01-24
BRPI1012321A2 (pt) 2016-03-15
SG10201403327WA (en) 2014-10-30
WO2010148223A2 (en) 2010-12-23
RU2567639C2 (ru) 2015-11-10
ES2656446T3 (es) 2018-02-27
CN102482349B (zh) 2017-08-25
EP2894167B1 (en) 2017-11-08
CA2765755A1 (en) 2010-12-23
HK1211961A1 (en) 2016-06-03
TWI510248B (zh) 2015-12-01
JP2012530496A (ja) 2012-12-06
IL239604A (en) 2016-08-31
ZA201109098B (en) 2012-08-29
EP2443150A2 (en) 2012-04-25
SG177265A1 (en) 2012-02-28
IL216835A0 (en) 2012-02-29
JP5785941B2 (ja) 2015-09-30
US20100322931A1 (en) 2010-12-23
EP2894167A1 (en) 2015-07-15
CO6480962A2 (es) 2012-07-16
MX2011013781A (es) 2012-05-29
AU2010262836B2 (en) 2015-05-28
UA104626C2 (ru) 2014-02-25
KR20120034739A (ko) 2012-04-12
CA2765755C (en) 2018-01-02
IL239604A0 (en) 2015-08-31
EP2443150B1 (en) 2015-01-21
CR20110653A (es) 2012-05-08
CN102482349A (zh) 2012-05-30
US9079953B2 (en) 2015-07-14
RU2011150916A (ru) 2013-07-27
WO2010148223A3 (en) 2011-03-03
BRPI1012321A8 (pt) 2016-09-27
ES2534355T3 (es) 2015-04-21
PE20120622A1 (es) 2012-05-26
AU2010262836A1 (en) 2011-12-22
CL2011003182A1 (es) 2012-07-20
NZ596837A (en) 2014-02-28
TW201103561A (en) 2011-02-01
ECSP12011584A (es) 2012-08-31

Similar Documents

Publication Publication Date Title
MX2011013781A (es) Anticuerpos anti-vegf y sus usos.
MX2015006859A (es) Anticuerpos anti-vegf y sus usos.
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
TN2012000040A1 (en) High affinity human antibodies to human angiopoietin -2
WO2011113019A3 (en) Ctla4 proteins and their uses
TN2012000555A1 (en) Antibodies to human gdf8
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
NZ706189A (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
JO2576B1 (en) Antibodies
MY165273A (en) Anti-cd48 antibodies and uses thereof
WO2011143318A3 (en) Anti-fgfr2 antibodies
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX2013007379A (es) Mutantes tipo papel lija de bacillus y metodos de uso de los mismos para mejorar el crecimiento vegetal, promover la salud de plantas y controlar enfermedades y plagas.
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека
GB201109238D0 (en) Antibodies
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
UA107836C2 (uk) Метод лікування хвороби альцгеймера
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.